Primary, or first line Hormone Therapy (ADT) can involve some different drugs. However, the constant standard includes either a GnRH agonist, such as leuprolide or an antagonist like Firmagon and an antiandrogen like Casodex.
According to researchers, the drug Metformin, when given alone or in combination, will reverse resistance and to Xtandi in certain mice models.
The NCCN has listed apalutamide (Erleada) as a category 1 recommendation for the treatment of men with non-metastatic castration-resistant prostate cancer (M0 & CRPC).
The European Medicines Agency (EMA) has recommended halting the use of the Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone due to a possible increased risk of death and fractures.
One of the questions that often come up is how long a man should use an antiandrogen drug like Casodex along with a GnRH agonist like Lupron or Zoladex? There is no question that an antiandrogen needs to be used before the first dosage of the agonist (Lupron), but should the antiandrogen be stopped or should it be continued along with the agonist (combining an antiandrogen along with the GnRH agonist is often referred to as a combined androgen blockade)?
First line Hormone Therapy (ADT) involves the use of different drugs. These drugs include three different classes of medications with three different modes of action. They include the GnRH agonists, such as leuprolide, antagonists like Firmagon and the antiandrogens like Casodex.
Preliminary data that suggests that men with cardiovascular disease being treated for metastatic prostate cancer may experience fewer cardiovascular events when treated with a GnRH antagonist, such as degarelix (Firmagon), compared with a GnRH agonist (Lupron, etc.).
Both Taxotere (docetaxel) and Zytiga (abiraterone) are approved for newly diagnosed men with very aggressive prostate cancer and who have not yet had any exposure to hormone therapy (ADT).
The two approvals lead us to the question, which of these treatment options would be best for you?
Axumin (fluciclovine F 18) injection has been added to the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology for Prostate Cancer.
This coming Wednesday, February 21, at 5:00 p.m. Eastern time (2:00 p.m. Pacific), Cancer ABCs will be collaborating with Cure Talks, The topic of the conversation will be It the recently launched “Metastatic Prostate Cancer Project”.
he FDA approved a new advanced hormone therapy drug (a next-generation androgen receptor inhibitor) for the treatment of men with non-metastatic castration-resistant prostate cancer (NM-CRPC). This drug with the trade name Erleada (aka apalutamide), is the first drug approved in this disease space.
The Food and Drug Administration approved the use of abiraterone acetate (Zytiga) with prednisone for men with high-risk, castration-sensitive, chemotherapy-naive metastatic prostate cancer, but there are some hitches and hurdles.
Two different trials, SPARTAN and PROSPER, are reporting top-line results in the treatment of men with nmCRPC. The full results of these trials will be presented today at the Genitourinary Cancer Symposium in San Francisco where Cancer ABCs is in attendance.
Early results from an international, open-label, phase 1/2 trial (NCT01934790) showed that it is possible to successfully re-treat men with the drug known as Xofigo (Ra-223). The study found that when used a second time, Xofigo was well tolerated and that it provides favorable effects on the cancer’s progression.
Like all of the other advanced prostate cancer treatments currently available, enzalutamide (Xtandi) lasts for a limited time. When Xtandi stops working we refer to this as developing resistance.
You have become castrate resistant and already have taken Provenge. Now, what treatment should be next? Currently, the two best options are either Zytiga (abiraterone) or Xtandi (enzalutamide). Which should come first?
There is often a choice is between using the LHRH agonist drug (Lupron, Trelstar) or using the gonadotrophin-releasing hormone (GnRH) antagonist like Firmagon.
This brings us to the question, which of these two drugs is superior?
The European Union has recently placed some restrictions on the use of the MRI contrast agent Gadolinium. There has been concern expressed by recent findings that Gadolinium doesn’t wholly disappear or wash out of a person’s body, but instead stays in a person’s brain.
Docetaxel combined with ADT, in men with hormone sensitive prostate cancer, when prescribed as per a study’s protocol led to significantly longer overall survival as well as other positive effects in men with metastatic hormone-sensitive prostate cancer who received only ADT.
Today is an important day, we launched the Metastatic Prostate Cancer Project (https://mpcproject.org/home ). The project will help understand an individual's genetics and their tumor genetics in relation to treatment responses. The project's findings will be fed back to the study's participants (which could be you) as well as prostate cancer researchers worldwide.